Post-Conference Perspectives: Key Takeaways From Recent Psoriasis Abstracts

home / post-conference-perspectives / post-conference-perspectives-key-takeaways-from-recent-psoriasis-abstracts

Aaron Farberg, MD, discusses how real-world studies like tildrakizumab’s help confirm efficacy and adherence outside trials, with multisite inclusion enhancing generalizability. Results aligned with clinical trials, highlighting better adherence. The VISIBLE study emphasized comorbidity impact, influencing clinical decisions and payer perspectives. Biosimilars’ role in clinical trials ensures safety and efficacy, with interchangeability gaining clinical adoption.

Episodes

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo